Cargando…
Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes
The antidiabetic sodium–glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin efficiently reduces heart failure (HF) hospitalization and cardiovascular death in type 2 diabetes (T2D). Empagliflozin-cardioprotection likely includes anti-inflammatory effects, regardless glucose lowering, but t...
Autores principales: | Giannattasio, Silvia, Citarella, Anna, Trocchianesi, Sofia, Filardi, Tiziana, Morano, Susanna, Lenzi, Andrea, Ferretti, Elisabetta, Crescioli, Clara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194473/ https://www.ncbi.nlm.nih.gov/pubmed/35712355 http://dx.doi.org/10.3389/fmolb.2022.879522 |
Ejemplares similares
-
Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte
por: Filardi, Tiziana, et al.
Publicado: (2019) -
Gestational Diabetes Mellitus: The Impact of Carbohydrate Quality in Diet
por: Filardi, Tiziana, et al.
Publicado: (2019) -
Identification and Validation of miR-222-3p and miR-409-3p as Plasma Biomarkers in Gestational Diabetes Mellitus Sharing Validated Target Genes Involved in Metabolic Homeostasis
por: Filardi, Tiziana, et al.
Publicado: (2022) -
The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence
por: Giannattasio, S., et al.
Publicado: (2018) -
Mitochondrial Chaperones and Proteases in Cardiomyocytes and Heart Failure
por: Chen, Zee, et al.
Publicado: (2021)